38
Participants
Start Date
June 30, 2025
Primary Completion Date
March 24, 2026
Study Completion Date
March 31, 2028
Ivonescimab
Ivonescimab is administered IV Q3W on Day 1 of each cycle. Ivonescimab is given at a dose of 20 mg/kg (a fixed dose of 3200 mg for ivonescimab should be used for patients ≥160 kg). The total duration of ivonescimab treatment is up to 24 months.
NOT_YET_RECRUITING
Besançon - CHU, Besançon
NOT_YET_RECRUITING
Brest - CHU, Brest
ACTIVE_NOT_RECRUITING
Caen - CHU, Caen
NOT_YET_RECRUITING
Clermont-Ferrand - Centre Jean Perrin, Clermont-Ferrand
ACTIVE_NOT_RECRUITING
Créteil - CHI, Créteil
ACTIVE_NOT_RECRUITING
Grenoble - CHU, Grenoble
ACTIVE_NOT_RECRUITING
Le Mans - CHG, Le Mans
RECRUITING
Lille - CHU, Lille
ACTIVE_NOT_RECRUITING
Marseille - APHM, Marseille
RECRUITING
Montpellier - CHU, Montpellier
ACTIVE_NOT_RECRUITING
Mulhouse - GHRMSA, Mulhouse
RECRUITING
Nantes - Hôpital Laennec, Nantes
ACTIVE_NOT_RECRUITING
Paris - Bichat, Paris
ACTIVE_NOT_RECRUITING
Bordeaux - CHU, Pessac
RECRUITING
Lyon - HCL, Pierre-Bénite
RECRUITING
Strasbourg - Nouvel Hôpital Civil, Strasbourg
ACTIVE_NOT_RECRUITING
Toulon - CHI, Toulon
ACTIVE_NOT_RECRUITING
Toulouse - CHU, Toulouse
RECRUITING
Tours - CHU, Tours
NOT_YET_RECRUITING
Metz - Hôpital Robert Schuman, Vantoux
Collaborators (1)
Summit Therapeutics
INDUSTRY
Intergroupe Francophone de Cancerologie Thoracique
OTHER